Tribromsalan

Summary

Tribromsalan (CHEMBL24944) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 449.92 Da · C13H8Br3NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL24944
Name	Tribromsalan
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	14868
ChEBI	CHEBI:127105
Molecular formula	C13H8Br3NO2
Molecular weight	449.92
InChIKey	KVSKGMLNBAPGKH-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br

IUPAC name: 3,5-dibromo-N-(4-bromophenyl)-2-hydroxybenzamide

ChEBI definition: A salicylanilide derivative with bromo- substituents at C-3 and C-5 of the salicylate moiety and at C-4 of the anilide moiety.

Also known as: ET-394, NSC-20526, Temasept iv, Tribromsalan, Tuasol 100, WR-34912, SID29215431, TRIBROMSALAN, SID144213540, SID170465542, SID144205253, SID144209640

Patent coverage: 793 distinct patent families (2,453 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,359 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Fructose-bisphosphate aldolase, Prelamin-A/C, Receptor tyrosine-protein kinase erbB-2, Epidermal growth factor receptor, Menin/Histone-lysine N-methyltransferase MLL, Prostaglandin G/H synthase 1, Tyrosine-protein kinase Lck, Mitogen-activated protein kinase 14.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPK1	6.21	IC50	623	nM	CHEMBL_ACT_7788724
MAPK14	6.15	IC50	715	nM	CHEMBL_ACT_7788726
CYP1A2	5.7	IC50	2000	nM	CHEMBL_ACT_7787783
CYP2C9	5.7	IC50	2000	nM	CHEMBL_ACT_7787789
PTGS1	5.68	IC50	2065	nM	CHEMBL_ACT_7787779
EGFR	5.53	IC50	2987	nM	CHEMBL_ACT_7788730
LCK	5.3	IC50	5015	nM	CHEMBL_ACT_7788736
LMNA	5.25	Potency	5623	nM	CHEMBL_ACT_3634438
ERBB2	5.22	IC50	5970	nM	CHEMBL_ACT_7788734

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).